Skip to main content
Premium Trial:

Request an Annual Quote

Genizon Receives $8.5M in Financing from Pfizer, BTF

NEW YORK (GenomeWeb News) - Genizon today said it has raised CA$10 million ($8.5 million) in series D equity financing from Pfizer and Dutch venture capital company BTF.
 
Pfizer’s investment is related to a licensing agreement it signed with Genizon in mid-January. At the time, Genizon said that Pfizer had taken an equity stake in the firm, but it did not disclose the amount of the investment.  
 
CFO Henry Bretecher told GenomeWeb News that the breakdown in investment was "roughly half and half" between Pfizer and BTF.
 
BTF has been an investor in Genizon, formerly called Galileo Genomics, since 2001, when it participated in a $16.5 million financing round. BTF also participated in the company’s $5.2 million round in 2003.
The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.